Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder23
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?20
Emerging drugs for the treatment of postsurgical pain18
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia18
New drugs targeting calcitonin gene-related peptide for the management of migraines15
A review of phase II and III drugs for the treatment and management of endometriosis14
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review14
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials14
Emerging medicines to improve the basic defect in cystic fibrosis13
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia12
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Emerging injectable therapies for osteoarthritis11
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials10
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?10
Emerging biological treatments for asthma9
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms9
Emerging drugs for the treatment of herpetic keratitis8
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion7
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials7
Cannabinoid treatment for the symptoms of autism spectrum disorder7
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder7
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria7
A review of emerging factor XI inhibitors7
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Expert opinion on emerging drugs for lung chronic graft-versus-host disease7
Recent advances in immune-based approaches for the treatment of esophagogastric cancer6
Emerging antiviral therapies and drugs for the treatment of influenza6
Correction6
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma6
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma6
How will tovorafenib change our treatment of pediatric low-grade glioma?6
Emerging tyrosine kinase inhibitors for head and neck cancer6
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials6
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis6
0.031736135482788